NASDAQ : KRSA
Korsana Biosciences, Inc. — Financial statements
Healthcare · Medical - Pharmaceuticals · United States
Last price 31.05 USD (Nov 2, 2026, 10:21 AM EST) · Market cap 1.41B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Selling, General & Admin | 7.75M | 4.51M | 318.00K |
| Research & Development | 44.16M | 32.78M | 336.00K |
| Operating Expenses | 51.91M | 37.29M | 654.00K |
| Operating Income | -51.91M | -37.29M | -654.00K |
| Interest & Investment Income | 2.83M | 1.65M | 126.00K |
| Pretax Income | -49.08M | -35.64M | -528.00K |
| Net Income | -49.08M | -35.64M | -528.00K |
| Net Income to Common | -49.08M | -35.64M | -528.00K |
| Shares Outstanding (Basic) | 3.67M | 2.92M | 1.51M |
| Shares Outstanding (Diluted) | 3.67M | 2.92M | 1.51M |
| EPS (Basic) | -13.37 | -12.20 | -0.35 |
| EPS (Diluted) | -13.37 | -12.20 | -0.35 |
| EBIT | -51.91M | -37.29M | -654.00K |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Cash & Equivalents | 134.16M | 154.13M | 10.11M |
| Cash & Short-Term Investments | 134.16M | 154.13M | 10.11M |
| Prepaid Expenses | 947.00K | 461.00K | |
| Total Current Assets | 135.11M | 154.60M | 10.11M |
| Total Assets | 137.70M | 154.60M | 10.11M |
| Accounts Payable | 176.00K | 68.00K | |
| Accrued Expenses | 7.40M | 12.31M | 10.00K |
| Total Current Liabilities | 7.77M | 12.49M | 78.00K |
| Other Long-Term Liabilities | 484.00K | 538.00K | |
| Total Liabilities | 9.19M | 13.03M | 78.00K |
| Common Stock | 1.00K | 1.00K | 1.00K |
| Additional Paid-In Capital | 2.21M | 1.76M | 153.00K |
| Retained Earnings | -49.24M | -35.73M | -88.00K |
| Total Common Equity | -47.03M | -33.97M | 66.00K |
| Shareholders' Equity | 128.51M | 141.57M | 10.03M |
| Total Liabilities & Equity | 137.70M | 154.60M | 10.11M |
| Net Cash (Debt) | 133.06M | 154.13M | 10.11M |
| Net Cash Per Share | 36.25 | 52.78 | 6.70 |
| Filing Date Shares Outstanding | 6.00M | 6.00M | 1.51M |
| Total Common Shares Outstanding | 6.00M | 6.00M | 1.51M |
| Working Capital | 127.34M | 142.11M | 10.03M |
| Book Value Per Share | -7.84 | -5.66 | 0.04 |
| Tangible Book Value | -47.03M | -33.97M | 66.00K |
| Tangible Book Value Per Share | -7.84 | -5.66 | 0.04 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Net Income | -49.08M | -35.64M | -528.00K |
| Stock-Based Compensation | 2.25M | 1.61M | 324.00K |
| Change in Accounts Payable | -262.00K | 108.00K | 408.00K |
| Change in Other Net Operating Assets | 5.25M | 11.52M | 60.00K |
| Operating Cash Flow | -41.84M | -22.41M | 264.00K |
| Issuance of Common Stock | 860.00K | 860.00K | 600.00K |
| Financing Cash Flow | 166.20M | 166.43M | 60.38M |
| Net Cash Flow | 124.19M | 144.03M | 60.65M |
| Levered Free Cash Flow | -9.75M | ||
| Unlevered Free Cash Flow | -9.75M | ||
| Change in Working Capital | 4.99M | 11.63M | 468.00K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Market Capitalization | 1.42B | 4.83M | 8.15M |
| Last Close Price | 30.14 | 8.89 | 22.54 |
| PB Ratio | 11.04 | 0.03 | 0.81 |
| P/TBV Ratio | 123.48 | ||
| P/OCF Ratio | 30.87 | ||
| Net Debt / Equity Ratio | -1.03 | -1.09 | -1.01 |
| Quick Ratio | 17.28 | 12.34 | 129.59 |
| Current Ratio | 17.40 | 12.38 | 129.59 |
| Return on Equity (ROE) | -47.02% | ||
| Return on Assets (ROA) | -28.30% | ||
| Return on Capital Employed (ROCE) | -40.00% | -26.20% | -6.50% |
| Earnings Yield | -42.94% | -737.34% | -6.48% |
| Buyback Yield / Dilution | -93.49% |